Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2001 Nov;108(10):1425-7.
doi: 10.1172/JCI14508.

More sweetness than light? A search for the causes of diabetic vasculopathy

J Igarashi  1 , T Michel
Affiliations
Comment

More sweetness than light? A search for the causes of diabetic vasculopathy

J Igarashi et al. J Clin Invest. 2001 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Signaling pathways that may mediate eNOS glycosylation and phosphorylation in vascular endothelial cells. The left half of the figure shows a model based on the results presented by Du et al. in a recent issue of the JCI (3). High-glucose treatment of endothelial cells is suggested to lead to the augmentation of ROS from mitochondria, leading to the activation of the glucosamine pathway by the activation of glutamine:fructose-6-phosphate amidotransferase (GFAT, the key enzyme in this pathway), ultimately increasing eNOS O-glycosylation. Basal levels of eNOS phosphorylation (green) at serine 1179 may be reciprocally attenuated by eNOS O-glycosylation with N-acetylglucosamine (GlcNAc; red). Various eNOS agonist receptors, such as those for insulin (17), VEGF (15), and sphingosine 1-phosphate (6), are also shown (right half of the figure). These receptors typically reside in or translocate to the caveolae (shown here as a membrane invagination). Each of these cell surface receptor pathways ultimately converges at the levels of eNOS enzyme activation, but each appears to involve distinct intervening calcium-mobilizing and protein kinase pathways to activate eNOS (6). Growth factors appear to activate both the α and the β isoforms of PI 3-kinase, whereas the G protein−coupled EDG-1 receptor activates only the PI 3-β isoform. Bradykinin does not appear to activate any PI 3-kinase isoform, and its effects are mediated by pertussis toxin−insensitive G proteins. By contrast, the platelet-derived agonist sphingosine 1-phosphate activates EDG-1 receptors that are coupled via pertussis toxin−sensitive G proteins. The effects of diabetes on these receptor-regulated dynamic eNOS phosphorylation pathways remain to be determined. It will be interesting to explore whether the counterbalancing of eNOS O-glycosylation and phosphorylation influences the development of diabetic vasculopathy, as suggested by Du et al. (3).
See this image and copyright information in PMC

Comment on

References

    1. McKinlay J, Marceau L. US public health and the 21st century: diabetes mellitus. Lancet. 2000;356:757–761. - PubMed
    1. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87–104. - PubMed
    1. Du XL, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001;108:1341–1348. - PMC - PubMed
    1. Hart GW. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem. 1997;66:315–335. - PubMed
    1. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146–2152. - PMC - PubMed

Substances